New Diabetes Pill Burns Fat, Keeps Muscle Mass Intact

Millions of people struggling with type 2 diabetes may soon have a new treatment option that addresses a problem doctors have been trying to solve for years. A newly developed pill helps lower blood sugar and burn fat while preserving muscle mass, something current medications often struggle with.

Researchers at Sweden's Karolinska Institutet and Stockholm University published their findings in the journal Cell after successful early trials. The treatment represents a completely different approach from popular GLP-1 drugs like Ozempic.

Instead of reducing appetite like weight loss injections do, this new pill activates metabolism directly inside skeletal muscle tissue. That means patients can improve their blood sugar without experiencing some of the common side effects associated with GLP-1 medications, including muscle loss, digestive problems, and reduced appetite.

The drug comes as a simple tablet rather than an injection, making it easier for patients to use. In early testing with 48 healthy volunteers and 25 people with type 2 diabetes, participants tolerated the treatment well with no major safety concerns.

Professor Tore Bengtsson from Stockholm University explains why muscle preservation matters so much. "Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy," he says.

The treatment uses a specially designed molecule called a β2 agonist that researchers engineered to boost muscle metabolism without overstimulating the heart. That's a significant breakthrough since heart side effects have historically prevented similar drugs from reaching patients.

The Ripple Effect

This discovery could benefit people in multiple ways beyond just treating diabetes. Because the pill works through a completely different mechanism than existing medications, doctors believe it could be used alone or combined with GLP-1 drugs for even better results.

Assistant Professor Shane C. Wright at Karolinska Institutet points out another advantage: "Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections."

The research involved an international team from Sweden, Denmark, and Australia, with funding from the Swedish Research Council and the Novo Nordisk Foundation. The next step is a larger Phase II clinical trial led by Atrogi AB to confirm whether the benefits observed in early studies hold up in larger groups of people with diabetes and obesity.

For the millions living with type 2 diabetes who worry about losing muscle strength while managing their condition, this research offers genuine hope for a healthier path forward.